# Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

> **NCT01601704** · PHASE3 · TERMINATED · sponsor: **Orexigen Therapeutics, Inc** · enrollment: 8910 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** NB32
- **DRUG:** PBO
- **BEHAVIORAL:** Weight Management Program

## Key facts

- **NCT ID:** NCT01601704
- **Lead sponsor:** Orexigen Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 8910 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01601704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01601704, "Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01601704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*